Trial Profile
Pilot Study: Single Arm, Multi-site, Open-label Study to Assess the Effectiveness of Peg-IFN-a2b in Decreasing the Levels of Cell-associated Integrated Viral DNA in HIV Chronic Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jul 2023
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 05 Jul 2023 Status changed from active, no longer recruiting to completed.
- 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections
- 31 Oct 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017.